• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neuroendocrine Cancer - Pipeline Review, H2 2012 Product Image

Neuroendocrine Cancer - Pipeline Review, H2 2012

  • Published: October 2012
  • 93 pages
  • Global Markets Direct

Neuroendocrine Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Neuroendocrine Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Cancer. Neuroendocrine Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neuroendocrine Cancer.
- A review of the Neuroendocrine Cancer products under development by companies READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Neuroendocrine Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Neuroendocrine Cancer 10
Neuroendocrine Cancer Therapeutics under Development by Companies 12
Neuroendocrine Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Neuroendocrine Cancer Therapeutics – Products under Development by Companies 20
Neuroendocrine Cancer Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Neuroendocrine Cancer Therapeutics Development 22
F. Hoffmann-La Roche Ltd. 22
Eli Lilly and Company 23
Novartis AG 24
Molecular Insight Pharmaceuticals, Inc. 25
Gradalis Inc. 26
Neuroendocrine Cancer – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
pasireotide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
everolimus - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
iobenguane I 131 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
yttrium Radiotherapy - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Sorafenib + RAD001 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RAD001 + Temozolomide - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
imatinib mesylate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Octreotide Acetate + Bevacizumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pazopanib hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
lanreotide acetate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Platinol + Gemzar + Interferon-Alpha + Hyperthermia Therapy - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
lithium carbonate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PTK-787 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Avastin + 5-Fluorouracil + Streptozotocin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pazopanib hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Octreotide + Bevacizumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Onalta + Retinoic Acid - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
sunitinib malate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
sunitinib malate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
everolimus - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
IMC-A12 + Octreotide - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pazopanib hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Irinotecan + Cisplatin + Octreotide Lar - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 68
Temozolomide + Vorinostat - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
pazopanib hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
X-82 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
pasireotide + everolimus - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Temozolomide + Pazopanib - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Capecitabine + Temozolomide + Bevacizumab - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Pbi-shRNA PDX-1 LP - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Cisplatin + Etoposide + Veliparib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Neuroendocrine Cancer Therapeutics – Drug Profile Updates 81
Neuroendocrine Cancer Therapeutics – Discontinued Products 88
Neuroendocrine Cancer Therapeutics - Dormant Products 89
Neuroendocrine Cancer – Product Development Milestones 90
Featured News & Press Releases 90
Oct 07, 2008: Neotropix Announces The Expansion Of On-going Clinical Trial For Adult Neuroendocrine Cancers 90
Oct 07, 2008: Neotropix Receives Orphan Drug Designation For NTX-010 From FDA. 90
May 17, 2006: Neotropix Receives FDA Approval To Begin Clinical Trials With First Investigational Cancer Drug For NTX-010. 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

List of Tables
Number of Products Under Development for Neuroendocrine Cancer, H2 2012 10
Products under Development for Neuroendocrine Cancer – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
F. Hoffmann-La Roche Ltd., H2 2012 22
Eli Lilly and Company, H2 2012 23
Novartis AG, H2 2012 24
Molecular Insight Pharmaceuticals, Inc., H2 2012 25
Gradalis Inc., H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Neuroendocrine Cancer Therapeutics – Drug Profile Updates 81
Neuroendocrine Cancer Therapeutics – Discontinued Products 88
Neuroendocrine Cancer Therapeutics – Dormant Products 89

List of Figures
Number of Products under Development for Neuroendocrine Cancer, H2 2012 10
Products under Development for Neuroendocrine Cancer – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos